ANI Names Vice President, Corticotropin Product Development
ANI Pharmaceuticals, Inc. has appointed Mark J. Ginski vice president, corticotropin product development. Ginski brings over 20 years of industry experience to the integrated specialty pharma company, most recently within Mallinckrodt Pharmaceuticals, where he was senior director, CMC and operations for autoimmune and rare diseases. Prior to this, he held various positions in the area of specialty drug development at Shire Pharmaceuticals, Alba Therapeutics, Cerecor Inc. and Questcor Pharmaceuticals.
You may also be interested in...
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.
New chief business officer named at Ovoca Bio, and a new chairman at Opthea Ltd.
Plus Sanofi and Translate Bio release preclinical data from their COVID-19 vaccine candidate, another entrant to the now crowded mRNA vaccine field.